Searle & CO. cut its position in shares of Pfizer, Inc. (NYSE:PFE) by 1.8% during the second quarter, Holdings Channel reports. The institutional investor owned 78,623 shares of the biopharmaceutical company’s stock after selling 1,429 shares during the period. Pfizer accounts for about 1.8% of Searle & CO.’s investment portfolio, making the stock its 10th largest position. Searle & CO.’s holdings in Pfizer were worth $2,641,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in PFE. Asset Planning Services Ltd. boosted its stake in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares in the last quarter. D. Scott Neal Inc. boosted its stake in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares in the last quarter. Orrstown Financial Services Inc. boosted its stake in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC bought a new stake in shares of Pfizer during the first quarter valued at $121,000. Finally, Cascade Investment Advisors Inc. boosted its stake in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,200 shares in the last quarter. Institutional investors and hedge funds own 70.10% of the company’s stock.

Shares of Pfizer, Inc. (PFE) traded down 0.51% during mid-day trading on Friday, reaching $33.25. The company’s stock had a trading volume of 12,928,473 shares. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.38. The stock has a market capitalization of $198.43 billion, a P/E ratio of 24.32 and a beta of 1.00. The company’s 50-day moving average price is $33.40 and its 200-day moving average price is $33.31.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. The business had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the previous year, the company posted $0.64 EPS. The company’s revenue was down 1.9% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 3.85%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s payout ratio is 94.12%.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.watchlistnews.com/pfizer-inc-nysepfe-shares-sold-by-searle-co/1479825.html.

Several equities research analysts have recently weighed in on PFE shares. Cowen and Company set a $43.00 price target on Pfizer and gave the company a “buy” rating in a research report on Monday, July 10th. Barclays PLC reiterated a “buy” rating and set a $38.00 price target on shares of Pfizer in a research report on Wednesday, May 3rd. Sanford C. Bernstein reiterated a “buy” rating and set a $37.00 price target on shares of Pfizer in a research report on Wednesday, May 3rd. UBS AG reiterated a “buy” rating and set a $38.00 price target on shares of Pfizer in a research report on Monday, July 31st. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $35.00 price target (up from $34.00) on shares of Pfizer in a research report on Friday, July 14th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $37.77.

In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.